- Founded
- 2024
- Employees
- 11-50
- Total Funding
- $100M
About Seaport Therapeutics
Seaport Therapeutics is a clinical-stage therapeutics company advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. The Company has a proven strategy of advancing clinically validated mechanisms previously held back by limitations that are overcome with its proprietary GlyphTM technology platform. All the therapeutic candidates in its pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely designed to enable oral bioavailability, bypass first-pass metabolism and reduce hepatotoxicity and other side effects.
Leadership at Seaport Therapeutics
The team at the top of the org chart.
SY
Sergey Yagoda
Executive Director
Open Jobs at Seaport Therapeutics (5)
Sort
Similar companies hiring
Top employers in Biotechnology